Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 27;13(3):486.
doi: 10.3390/cancers13030486.

Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center

Richard E Evenhuis  1 , Ibtissam Acem  1   2 , Anja J Rueten-Budde  3 , Diederik S A Karis  1 , Marta Fiocco  3 , Desiree M J Dorleijn  1 , Frank M Speetjens  4 , Jakob Anninga  5 , Hans Gelderblom  4 , Michiel A J van de Sande  1   5
Affiliations

Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center

Richard E Evenhuis et al. Cancers (Basel). .

Abstract

Age is a known prognostic factor for many sarcoma subtypes, however in the literature there are limited data on the different risk profiles of different age groups for osteosarcoma survival. This study aims to provide an overview of survival in patients with high-grade osteosarcoma in different age groups and prognostic variables for survival and local control among the entire cohort. In this single center retrospective cohort study, 402 patients with skeletal high-grade osteosarcoma were diagnosed and treated with curative intent between 1978 and 2017 at the Leiden University Medical Center (LUMC). Prognostic factors for survival were analyzed using a Cox proportional hazard model. In this study poor overall survival (OS) and event-free survival (EFS) were associated with increasing age. Age groups, tumor size, poor histopathological response, distant metastasis (DM) at presentation and local recurrence (LR) were important independent prognostic factors influencing OS and EFS. Differences in outcome among different age groups can be partially explained by patient and treatment characteristics.

Keywords: age groups; chemotherapy; local recurrence; metastasis; osteosarcoma; prognosis; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart patient selection. Legend; LUMC = Leiden University Medical Center, CTx = Chemotherapy.
Figure 2
Figure 2
Kaplan–Meier (KM) estimation of OS in the total cohort divided by age group. Legend: OS = overall survival, cum survival = cumulative survival, LDFU = last date of follow-up.
Figure 3
Figure 3
KM estimation of OS in the total cohort (upper panel) and of patients with and without distant metastasis (lower panel). Legend: OS = overall survival, DM = distant metastasis at presentation, cum survival = cumulative survival, LDFU = last date of follow-up.
Figure 4
Figure 4
KM estimation of EFS in total cohort divided by age group. Legend: EFS = event-free survival, cum survival = cumulative survival.
Figure 5
Figure 5
KM estimation of EFS of total cohort. Legend: EFS = Event-free survival, cum survival = cumulative survival.
Figure 6
Figure 6
Landmark analysis of patients with and without LR 24 months post-surgery. Legend: LR = local recurrence, cum survival = cumulative survival, LDFU = last date of follow-up.
See this image and copyright information in PMC

References

    1. The ESMO/European Sarcoma Network Working Group Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014;25:iii113–iii123. doi: 10.1093/annonc/mdu256. - DOI - PubMed
    1. Ferrari S., Bertoni F., Mercuri M., Picci P., Giacomini S., Longhi A., Bacci G. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. Ann. Oncol. 2001;12:1145–1150. doi: 10.1023/A:1011636912674. - DOI - PubMed
    1. Smeland S., Bielack S.S., Whelan J., Bernstein M., Hogendoorn P., Krailo M.D., Gorlick R., Janeway K.A., Ingleby F.C., Anninga J., et al. Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur. J. Cancer. 2019;109:36–50. doi: 10.1016/j.ejca.2018.11.027. - DOI - PMC - PubMed
    1. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., Kotz R., Salzer-Kuntschik M., Werner M., Winkelmann W., et al. Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J. Clin. Oncol. 2002;20:776–790. doi: 10.1200/JCO.2002.20.3.776. - DOI - PubMed
    1. Zhang C., Guo X., Xu Y., Han X., Cai J., Wang X., Wang G. Lung metastases at the initial diagnosis of high-grade osteo-sarcoma: Prevalence, risk factors and prognostic factors. A large population-based cohort study. Sao Paulo Med. J. 2019;137:423–429. doi: 10.1590/1516-3180.2018.0381120619. - DOI - PMC - PubMed

LinkOut - more resources